ARTICLE | Company News
Catalyst Biosciences, Wyeth deal
July 6, 2009 7:00 AM UTC
Catalyst granted Wyeth exclusive, worldwide rights to develop and commercialize its CB 813, a recombinant human coagulation Factor VIIa (rhFVIIa) in preclinical development to treat and prevent acute...